151 related articles for article (PubMed ID: 15930279)
1. Tachyplesin activates the classic complement pathway to kill tumor cells.
Chen J; Xu XM; Underhill CB; Yang S; Wang L; Chen Y; Hong S; Creswell K; Zhang L
Cancer Res; 2005 Jun; 65(11):4614-22. PubMed ID: 15930279
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of tachyplesin I injury to bacterial membranes and intracellular enzymes, determined by laser confocal scanning microscopy and flow cytometry.
Hong J; Guan W; Jin G; Zhao H; Jiang X; Dai J
Microbiol Res; 2015 Jan; 170():69-77. PubMed ID: 25267486
[TBL] [Abstract][Full Text] [Related]
3. RGD-Tachyplesin inhibits tumor growth.
Chen Y; Xu X; Hong S; Chen J; Liu N; Underhill CB; Creswell K; Zhang L
Cancer Res; 2001 Mar; 61(6):2434-8. PubMed ID: 11289111
[TBL] [Abstract][Full Text] [Related]
4. Effects of tachyplesin and n-sodium butyrate on proliferation and gene expression of human gastric adenocarcinoma cell line BGC-823.
Shi SL; Wang YY; Liang Y; Li QF
World J Gastroenterol; 2006 Mar; 12(11):1694-8. PubMed ID: 16586536
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Tachyplesin Peptides and Their Cyclized Analogues to Improve Antimicrobial and Anticancer Properties.
Vernen F; Harvey PJ; Dias SA; Veiga AS; Huang YH; Craik DJ; Lawrence N; Troeira Henriques S
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31455019
[TBL] [Abstract][Full Text] [Related]
6. Identification of C1q as a Binding Protein for Advanced Glycation End Products.
Chikazawa M; Shibata T; Hatasa Y; Hirose S; Otaki N; Nakashima F; Ito M; Machida S; Maruyama S; Uchida K
Biochemistry; 2016 Jan; 55(3):435-46. PubMed ID: 26731343
[TBL] [Abstract][Full Text] [Related]
7. Effects of tachyplesin I on human U251 glioma stem cells.
Ding H; Jin G; Zhang L; Dai J; Dang J; Han Y
Mol Med Rep; 2015 Apr; 11(4):2953-8. PubMed ID: 25434611
[TBL] [Abstract][Full Text] [Related]
8. High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component.
Boackle RJ; Connor MH; Vesely J
Mol Immunol; 1993 Feb; 30(3):309-19. PubMed ID: 8433709
[TBL] [Abstract][Full Text] [Related]
9. Deletion of all cysteines in tachyplesin I abolishes hemolytic activity and retains antimicrobial activity and lipopolysaccharide selective binding.
Ramamoorthy A; Thennarasu S; Tan A; Gottipati K; Sreekumar S; Heyl DL; An FY; Shelburne CE
Biochemistry; 2006 May; 45(20):6529-40. PubMed ID: 16700563
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Study of Antitumor Effect of Antimicrobial Peptide Tachyplesin I in Combination with Cisplatin.
Kuzmin DV; Emel'yanova AA; Kalashnikova MB; Panteleev PV; Ovchinnikova TV
Bull Exp Biol Med; 2018 Jun; 165(2):220-224. PubMed ID: 29922995
[TBL] [Abstract][Full Text] [Related]
11. Modified horseshoe crab peptides target and kill bacteria inside host cells.
Amiss AS; von Pein JB; Webb JR; Condon ND; Harvey PJ; Phan MD; Schembri MA; Currie BJ; Sweet MJ; Craik DJ; Kapetanovic R; Henriques ST; Lawrence N
Cell Mol Life Sci; 2021 Dec; 79(1):38. PubMed ID: 34971427
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Proteomic Profiling of Tachyplesin I Targets in U251 Gliomaspheres.
Li X; Dai J; Tang Y; Li L; Jin G
Mar Drugs; 2017 Jan; 15(1):. PubMed ID: 28106765
[TBL] [Abstract][Full Text] [Related]
13. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.
Barilla-LaBarca ML; Liszewski MK; Lambris JD; Hourcade D; Atkinson JP
J Immunol; 2002 Jun; 168(12):6298-304. PubMed ID: 12055245
[TBL] [Abstract][Full Text] [Related]
14. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma.
Skliris A; Happonen KE; Terpos E; Labropoulou V; Børset M; Heinegård D; Blom AM; Theocharis AD
Eur J Immunol; 2011 Feb; 41(2):437-49. PubMed ID: 21268013
[TBL] [Abstract][Full Text] [Related]
15. Specific inhibition of the classical complement pathway by C1q-binding peptides.
Roos A; Nauta AJ; Broers D; Faber-Krol MC; Trouw LA; Drijfhout JW; Daha MR
J Immunol; 2001 Dec; 167(12):7052-9. PubMed ID: 11739526
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
17. Covalent binding of C3b to C4b within the classical complement pathway C5 convertase. Determination of amino acid residues involved in ester linkage formation.
Kim YU; Carroll MC; Isenman DE; Nonaka M; Pramoonjago P; Takeda J; Inoue K; Kinoshita T
J Biol Chem; 1992 Feb; 267(6):4171-6. PubMed ID: 1740458
[TBL] [Abstract][Full Text] [Related]
18. Action mechanism of tachyplesin I and effects of PEGylation.
Imura Y; Nishida M; Ogawa Y; Takakura Y; Matsuzaki K
Biochim Biophys Acta; 2007 May; 1768(5):1160-9. PubMed ID: 17320042
[TBL] [Abstract][Full Text] [Related]
19. Complement-Mediated Neutralization of a Potent Neurotropic Human Pathogen, Chandipura Virus, Is Dependent on C1q.
Kunnakkadan U; Nag J; Kumar NA; Mukesh RK; Suma SM; Johnson JB
J Virol; 2019 Oct; 93(19):. PubMed ID: 31315998
[TBL] [Abstract][Full Text] [Related]
20. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b.
Kozono H; Kinoshita T; Kim YU; Takata-Kozono Y; Tsunasawa S; Sakiyama F; Takeda J; Hong K; Inoue K
J Biol Chem; 1990 Aug; 265(24):14444-9. PubMed ID: 2387864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
